Skip to Main Content Skip to Site Map Skip to Accessibility Statement
Home Formulary 3.0 Respiratory System 3.2 Corticosteroids 3.2.4 Triple therapy inhalers [COPD]

3.2.4 Triple therapy inhalers [COPD]

ChoiceDrugCarbon FootprintDose Counter Present (D)
Formulary choices (COPD)Beclometasone/formoterol/glycopyrronium
Trimbow® NEXThaler DPI 88/5/9D
Or
Trimbow® MDI 87/5/9 NB - the higher strength MDI 172/5/9 is not licensed for use in COPD

D
Fluticasone furoate/vilanterol/umeclidinium
Trelegy® Ellipta DPI 92/55/22D
Budesonide/formoterol/glycopyrronium
Trixeo® Aerosphere MDI 5/7.2/160

D

Prescribing Notes

  • Triple therapy inhalers may offer a more convenient, cost-effective, lower carbon option for patients requiring triple therapy. They should only be prescribed where patient meets criteria for triple therapy use – refer to NICE NG115 COPD and GOLD report for further guidance.
  • Trimbow® MDI (beclometasone / formoterol / glycopyrronium) is also accepted for use as maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta-2 agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. For further information see SMC. Please note that both the 172/5/9 and the 87/5/9 strengths of Trimbow® MDI are licensed for asthma but only the lower strength Trimbow® 87/5/9 inhaler is licensed for COPD.

Also in this Section